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Abstract
 
Cytotoxic T lymphocytes (CTLs) destroy target cells through a mechanism involving the exo-
cytosis of cytolytic granule components including granzyme B (grB) and perforin, which have
been shown to induce apoptosis through caspase activation. However, grB has also been linked
with caspase-independent disruption of mitochondrial function. We show here that cyto-
chrome c release requires the direct proteolytic cleavage of Bid by grB to generate a 14-kD
grB-truncated product (gtBid) that translocates to mitochondria. In turn, gtBid recruits Bax to
mitochondria through a caspase-independent mechanism where it becomes integrated into the
membrane and induces cytochrome c release. Our results provide evidence for a new pathway
by which CTLs inflict damage and explain the caspase-independent mechanism of mitochon-
drial dysfunction.
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Introduction
 
CTLs are cells which participate in adaptive immune re-
sponses such as the elimination of virus-infected and tumor
cells, as well as transplant rejection (1–4). The destruction
of target cells is believed to involve either engagement of
the Fas receptor or granule exocytosis. Fas ligation and oli-
gomerization lead to the formation of the death-inducing
 
signaling complex (DISC),
 
1
 
 which begins with recruitment
of Fas-associated death domain (FADD)/mediator of re-
ceptor-induced toxicity (MORT)1 to the cytoplasmic
death domains of Fas (5). FADD acts as an adapter mole-
cule between the Fas receptor and the prodomain of
caspase-8 (6, 7), a member of the caspase family of cysteine
proteinases (cysteinyl aspases). These enzymes exist in cells
as inactive zymogens but are proteolytically cleaved fol-
lowing aspartate residues to become activated in response
to an apoptotic stimulus (for reviews, see references 8–10).
The recruitment of caspase-8 to the DISC brings identical
molecules into close proximity and allows for catalytic acti-
vation. In cells where caspase-8 is efficiently recruited to
the DISC, activated caspase-8 directly acts on caspase-3
(11) to initiate the effector stages of the apoptotic program,
including chromatin condensation, DNA fragmentation,
membrane alterations, and cytoskeletal rearrangements
(12–16). However, in cells such as Jurkat, where recruit-
ment of capsase-8 to the DISC is relatively inefficient, in-
direct activation of caspase-3 mediated through a mito-
chondrial pathway takes precedence. This occurs through
proteolytic activation of Bid, a proapoptotic member of
the Bcl-2 family (17–19). Caspase-8 cleavage of 26-kD hu-
man Bid following Asp59 generates a COOH-terminal
cleavage product of 15 kD (17, 18, 20). Truncated (t)Bid
translocates to mitochondria where it causes the permeabi-
lization of the outer mitochondrial membrane through a
poorly defined mechanism leading to the release of cyto-
chrome c from the intermembrane space (17–19). Once
released to the cytoplasm, cytochrome c acts as a cofactor
in conjunction with Apaf-1, procaspase-9, and ATP/dATP
 
to induce activation of caspase-9 and subsequently cas-
pase-3 (21, 22).
The second mechanism used by CTLs to kill targets in-
volves the calcium-dependent exocytosis of CTL-derived
 
Address correspondence to R. Chris Bleackley, Dept. of Biochemistry,
463 Medical Sciences Bldg., University of Alberta, Edmonton, Alberta
T6G 2H7, Canada. Phone: 780-492-3968; Fax: 780-492-0886; E-mail:
chris.bleackley@ualberta.ca
 
1
 
Abbreviations used in this paper: 
 
Ad, adenovirus; DISC, death-inducing
signaling complex; grB, granzyme B; HRP, horseradish peroxidase; t,
truncated. 
1392
 
Granzyme B–mediated Cytochrome c Release Is Regulated by Bid and Bax
 
granule proteins and their uptake by the target cell. Among
the granule components are the pore-forming protein per-
forin and several granule proteinases or granzymes, which
gain entry into the target cell through a poorly defined
mechanism (for reviews, see references 1, 2–4). Granzyme
B (grB), the prototypic member of the granzymes, is a
serine proteinase with a unique specificity among mamma-
lian serine proteinases for cleavage on the carboxyl side of
aspartate residues (23). Several caspases contain cleavage
sites potentially recognized by grB (24, 25), implying that
grB may activate caspases in the target cell after uptake.
Indeed, caspases, including caspase-3 (CPP32/Apopain/
Yama), caspase-6 (Mch2), caspase-7 (Mch3/CMH-1/ICE-
LAP3), caspase-8 (FLICE/MACH/Mch5), capsase-9 (ICE-
LAP6/Mch6), and caspase-10 (Mch4), are cleaved by grB
in vitro (6, 26–34). In addition, processed caspases-1 (ICE),
-3, -7, and -8 are found in whole cells after treatment with
purified grB and perforin or a replication-deficient adeno-
virus (Ad), or in response to treatment with human CTLs
(29, 35–38).
GrB can proteolytically cleave caspase-3 both in vitro
and in whole cells in the presence of the broad-spectrum
caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoro-
methyl ketone (zVAD-fmk [26, 36, 37]). This implies that
grB directly activates caspase-3, leading to apoptosis. In ad-
dition, it was recently shown that treatment of targets
with grB and Ad or perforin, or whole CTLs, leads to
mitochondrial disruptions through a caspase-independent
mechanism (39, 40). These data suggest that grB can also
induce necrotic cell death without caspase activation.
However, it was not known whether grB acted directly on
mitochondria or indirectly through the proteolytic activa-
tion or inactivation of a cellular substrate(s).
We show here that Bid is required for the release of cy-
tochrome c in response to grB. Bid is known to be cleaved
by grB to generate a 14-kD grB-truncated Bid fragment
(herein designated gtBid) that is distinct from tBid (18, 35).
Here we present evidence that, once generated, gtBid
translocates to mitochondria where it recruits the proapop-
totic Bcl-2 family member, Bax, to the mitochondrial
membrane. Bax becomes integrated into the membrane to
induce release of cytochrome c through a caspase-indepen-
dent mechanism. Importantly, Bcl-2 does not inhibit Bid
cleavage and translocation to mitochondria but does pre-
vent Bax insertion and cytochrome c release after treatment
with grB.
 
Materials and Methods
 
Cell Culture and Reagents.
 
The human T cell lymphoma line
Jurkat (American Type Culture Collection) was grown in RPMI
(Life Technologies) supplemented with 10% fetal bovine serum
(Hyclone) and 100 
 
m
 
M 2-mercaptoethanol (RHFM). GrB was
purified as described previously (41). Stable transfected cells
were prepared as follows. The Bcl-2 gene was subcloned into
the XhoI site of the eukaryotic expression vector BMGneo
(42). Jurkat cells were stably transfected with 10 
 
m
 
g of NotI lin-
earized DNA by electroporation (250 V, 250 
 
m
 
F). Stably trans-
 
fected cells were selected in RHFM containing 1 mg/ml of
G418 (Life Technologies) and cloned by limiting dilution. After
selection, cells were routinely grown in RHFM containing 800
 
m
 
g/ml of G418. Jack Gauldie (McMaster University, Hamilton,
Ontario, Canada) provided replication-deficient Ad (type 5).
zVAD-fmk was from Kamiya Biochemicals. Anti–human Fas
IgM antibody (clone CH11) was from Upstate Biotechno-
logy. Monoclonal anti–human cytochrome c antibody (clone
7H8.2C12) was from BD PharMingen. Rabbit polyclonal anti-
Bax antiserum (N-20) was from Santa Cruz Biotechnology, Inc.
The goat anti–mouse and goat anti–rabbit horseradish peroxi-
dase (HRP)-conjugated secondary antibodies were from Bio-
Rad Laboratories. The rabbit anti–mouse Bid antiserum and the
pET-15b vector containing His-tagged human Bid were pro-
vided by Xiaodong Wang (Howard Hughes Medical Institute,
Dallas, TX). Sigma-Aldrich provided all other reagents unless
otherwise stated.
 
Subcellular Fractionation.
 
Subcellular fractionation of Jurkat
cells was performed as described (43). In brief, 1–6 
 
3
 
 10
 
8
 
 cells
were collected for 10 min at 2,000 
 
g
 
 (3,500 rpm in a Sorvall GSA
rotor) and washed once with PBS. The pellet was washed once
with buffer A (20 mM morpholino propane sulfonic acid
[MOPS], pH 7.4, 100 mM sucrose, 1 mM EGTA) and then re-
suspended in a volume of buffer B (20 mM MOPS, pH 7.4, 100
mM sucrose, 1 mM EGTA, 5% Percoll, and 191 
 
m
 
g/ml digito-
nin) giving a final cell density of 2 
 
3
 
 10
 
7
 
 cells/ml. After a 15-min
incubation on ice with occasional stirring, the cells were spun at
2,500 
 
g
 
 (4,500 rpm in a Sorvall SS-34 rotor) for 10 min at 4
 
8
 
C.
The pellet, containing nuclei and cell debris, was discarded. The
supernatant was further fractionated by centrifugation at 15,000 
 
g
 
(11,500 rpm in a Sorvall SS-34 rotor) for 15 min at 4
 
8
 
C. The mi-
tochondrial fraction, a loose fluffy layer at the bottom of the tube,
was collected, washed three times with buffer A, and then resus-
pended in buffer A. The supernatant was spun at 100,000 
 
g
 
(39,000 rpm in a Beckman 70Ti rotor) for 1 h at 4
 
8
 
C. The S-100
cytosolic fraction is herein referred to as the cytosol. Protein con-
centrations were determined using a bicinchoninic acid (BCA)
kit (Pierce Chemical Co.).
 
Expression and Purification of Recombinant Bid.
 
His-tagged human
rBid in the pET-15b vector was expressed in competent BL21
 
Escherichia coli
 
 and purified as described (17).
 
Immunodepletion of Bid from Jurkat Cytosol.
 
Anti–human Bid anti-
bodies (C-20; Santa Cruz Biotechnology, Inc.; or PBS alone for
the mock control) were incubated in 325 
 
m
 
l PBS containing
4.5% protein A– and protein G–agarose (Amersham Pharmacia
Biotech) for 3 h at 4
 
8
 
C with rocking. The antibody-bound pro-
tein A/G beads were washed in buffer A and then incubated with
170 
 
m
 
g of Jurkat cytosol at 4
 
8
 
C for 18 h with rocking. The aga-
rose beads were then pelleted and the resulting supernatants were
labeled as C (
 
2
 
Bid) or C (mock) for Bid-depleted or mock-
depleted cytosol, respectively. Immunodepletion of Bid was veri-
fied by Western blotting.
 
In Vitro Assays.
 
Purified mitochondria (10–20 
 
m
 
g) were mixed
either with an equivalent amount of cytosol (10–20 
 
m
 
g) or an
equivalent volume of buffer A alone as indicated. GrB (0.5 
 
m
 
g)
was added for 30 min at room temperature in the presence or
absence of 100 
 
m
 
M zVAD-fmk. The mixtures were then spun
for 5 min at 16,000 
 
g
 
 (14,000 rpm in an Eppendorf tabletop mi-
crofuge). The supernatants were transferred to fresh tubes and
the pellets (mitochondria) were resuspended in a volume of
buffer A equivalent to the initial sample volume. Pellets and su-
pernatants were then mixed with 6
 
3
 
 SDS loading buffer, boiled
for 10 min, and loaded onto 15% SDS–polyacrylamide gels. Pro- 
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teins were resolved at 200 V for 
 
z
 
50 min and subsequently
transferred to nitrocellulose (Micron Separations Inc.) at 150 mA
for 1.25 h in a semidry blotting apparatus (Tyler Instruments
Inc.). Membranes were blocked overnight in 5% milk proteins
(Carnation) in PBST (PBS plus 0.1% Tween 20 [Fisher Scien-
tific]). Proteins were visualized with a monoclonal anti–human
cytochrome c antibody (1:2,000), followed by a goat anti–mouse
HRP-conjugated secondary antibody (1:3,000), followed by en-
zyme-linked chemiluminescence (Amersham Pharmacia Bio-
tech). Immunoblotting for Bid and Bax was performed as for
cytochrome c with the following modifications. Rabbit anti–
mouse Bid (which cross-reacts with human) was used at 1:4,000
to 1:8,000. The goat anti–rabbit HRP-conjugated secondary
was used at 1:20,000. Rabbit anti–human Bax was used at 1:400
to 1:1,000.
 
Alkaline Extraction of Mitochondria.
 
Mitochondria were incu-
bated under the conditions indicated. After incubation, mito-
chondria were centrifuged at 16,000 
 
g
 
 (14,000 rpm in an Eppen-
dorf tabletop microfuge) for 10 min at 4
 
8
 
C. The supernatants
(preextraction supernatants) were removed, and to them was
added 6
 
3
 
 SDS loading buffer followed by boiling for 10 min.
The mitochondria were resuspended in 0.1 M Na
 
2
 
CO
 
3
 
 for 30
min on ice. After this incubation, the extracted mitochondria
were centrifuged at 100,000 
 
g
 
 (39,000 rpm in a Beckman Ti100.2
rotor) for 10 min at 4
 
8
 
C. The supernatants were discarded and
the pellets were resuspended in a volume of buffer A equivalent
to the volume of the starting samples as well as 6
 
3
 
 SDS loading
buffer. These samples were boiled for 10 min and the extracted
pellets and preextraction supernatants were resolved on 15%
polyacrylamide gels followed by transfer to nitrocellulose. The
blots were probed for Bax as outlined above.
 
Whole Cell Assays.
 
Jurkat cells were treated with grB and Ad
in the presence or absence of 100 
 
m
 
M zVAD-fmk and the mito-
chondrial and cytosolic fractions were separated as described pre-
viously (39). Immunoblotting was performed as outlined above.
 
Alkaline Extraction of Whole Cells.
 
Jurkat cells (8 
 
3
 
 10
 
6
 
/sam-
ple) were treated as indicated. After treatment, cells were washed
once with PBS and then resuspended in 400 
 
m
 
l digitonin lysis
buffer (75 mM NaCl, 1 mM NaH
 
2
 
PO
 
4
 
, 8 mM Na
 
2
 
HPO
 
4
 
, 250
mM sucrose, and 191 
 
m
 
g/ml digitonin). Cells were incubated on
ice for 15 min, followed by centrifugation at 300 
 
g
 
 (2,000 rpm in
an Eppendorf microfuge) at 4
 
8
 
C. The pellet, containing nuclei
and unbroken cells, was discarded. The supernatant was then cen-
trifuged at 16,000 
 
g
 
 (14,000 rpm in an Eppendorf microfuge) for
15 min at 4
 
8
 
C. The supernatant contained the cytosol. The pellet,
containing mitochondria, was subjected to alkaline extraction
with 400 
 
m
 
l of 0.1 M Na
 
2
 
CO
 
3
 
 for 30 min on ice followed by
centrifugation at 100,000 
 
g
 
 (39,000 rpm in a Beckman 100.2 ro-
tor) for 10 min at 4
 
8
 
C. The supernatant was discarded and the
membrane pellets were resuspended with 6
 
3
 
 SDS loading buffer
followed by boiling. The preextraction supernatant (cytosol) and
the extracted mitochondrial proteins were resolved by SDS-
PAGE, followed by transfer to nitrocellulose and immunoblot-
ting for Bax.
 
Densitometric Analysis.
 
Blots were scanned at a resolution of
400 pixels per inch using an Agfa Arcus II scanner with Agfa Fo-
toLook Software (v3.0) and imported into Adobe Photoshop
 
®
 
(v5.5). The scanned images were saved as grayscale PICT files
and imported into Fuji Photo Film Co. Image Gauge software
(v3.0). An area of 84 square pixels was then placed about each
band and the pixel density was determined by the software. Val-
ues were plotted as pixel density per unit area and are displayed as
arbitrary units.
 
Results
 
A Cytosolic Factor Is Required for GrB-mediated Cytochrome
c Release.
 
We have previously shown that grB can induce
the loss of inner mitochondrial membrane potential and cy-
tochrome c efflux from mitochondria through a caspase-
independent mechanism (39). To investigate whether grB
acted alone or in concert with additional factors, we devel-
oped an in vitro system that used purified mitochondria
from Jurkat cells. Jurkat mitochondria were incubated ei-
ther with grB alone or Jurkat cytosol and grB in various
combinations for 30 min at room temperature either in the
presence or absence of the broad-spectrum caspase inhibi-
tor, zVAD-fmk. After this incubation, the mixture was
centrifuged and the mitochondrial pellets were separated
from the supernatants. Proteins in the separated samples
were resolved by electrophoresis and examined for the
presence of cytochrome c by immunoblotting (Fig. 1).
In the absence of treatment, cytochrome c was detect-
able only in the mitochondrial pellet and not in the super-
natant (Fig. 1 A, lane 1, and compare lanes 12 and 2).
When cytosol (Fig. 1 A, lanes 13 and 3) or grB (Fig. 1 A,
lanes 14 and 4) was added separately to mitochondria, cyto-
chrome c release was not detected. However, when grB
was added to mitochondria in conjunction with cytosol,
cytochrome c efflux from mitochondria was observed (Fig.
1 A, compare lanes 15 and 5). Importantly, the same results
were observed in the presence of 100 
 
m
 
M zVAD-fmk (Fig.
1 A, compare lanes 33 and 24). Therefore, cytochrome c
release did not occur through a direct interaction of grB
with mitochondria. Rather, a zVAD-fmk–insensitive cyto-
solic factor (or factors) was required.
 
Bid Is Required for GrB-mediated Cytochrome c Release.
 
One possible candidate for the cytosolic factor required by
grB to elicit cytochrome c release was the proapoptotic
Bcl-2 family member Bid. As outlined in the introduction,
Bid has been shown to play a role in apoptosis induced af-
ter ligation of the Fas and TNF receptors (17–19). In addi-
tion to the caspase cleavage site at Asp59, Bid contains an
excellent cleavage site for grB (IEAD
 
75
 
). We, and others,
have recently shown that in the presence of grB, in vitro–
transcribed/translated Bid is cut into a 14-kD product (18,
35). Moreover, Bid cleavage occurs in whole cells after
treatment with grB and Ad
 
 
 
(35).
To determine if grB-mediated cytochrome c efflux was
dependent on Bid, we immunodepleted Bid from the cyto-
solic extract before its addition to mitochondria plus grB.
The efficiency of Bid immunodepletion was assessed by
Western blotting (Fig. 1 B). Mock-immunodepleted cyto-
sol generated the same cytochrome c efflux pattern as non-
immunodepleted cytosol (Fig. 1 A, compare lanes 6 and 16
with lanes 15 and 5). In contrast, when the Bid-depleted
cytosol was added to mitochondria in the presence of grB,
no release of cytochrome c was observed (Fig. 1 A, com-
pare lanes 7 and 17). When rBid was added back to the im-
munodepleted cytosol, cytochrome c efflux was restored
but only upon the addition of grB (Fig. 1 A, lanes 8 and
18). These data suggested that the loss of cytochrome c 
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from mitochondria in response to grB treatment was de-
pendent on the presence of cytosolic Bid.
To confirm the dependence of cytochrome c release on
Bid, mitochondria were treated with rBid in the absence of
cytosol and in the presence or absence of grB. Without
grB, rBid was unable to induce cytochrome c release from
mitochondria (Fig. 1 A, lanes 9 and 19). Importantly, in
contrast to rBid alone, treatment of mitochondria with
rBid in conjunction with grB led to the complete loss of
cytochrome c (Fig. 1 A, lanes 10 and 20). These results im-
ply that grB-dependent proteolytic cleavage of Bid leads to
the generation of a fragment that is active in mediating ef-
fects on mitochondria.
These experiments were repeated in the presence of
zVAD-fmk with identical results (Fig. 1 A, compare lanes
21–29 to 30–38). Thus, the grB-mediated cytochrome c
efflux in this system occurred independently of caspases,
consistent with the caspase-independent cytochrome c loss
in whole cells seen after treatment with grB and Ad (39).
Collectively, these data show that Bid is necessary for grB-
mediated cytochrome c release from mitochondria, after
direct activation by this proteinase.
 
GrB-mediated Target Cell Death Induces Translocation of gt-
Bid from the Cytosol to Mitochondria.
 
In response to ligation
of Fas or TNF receptors, Bid is cleaved by caspase-8 to gen-
erate 15-kD tBid. Translocation of tBid from the cytosol to
mitochondria has been shown to be critical for cytochrome
c release to occur (17–19). We wished to know if the
smaller, granzyme-cleaved gtBid fragment also translocated
to mitochondria in whole cells in response to grB and Ad.
Jurkats cells were treated either with soluble anti-Fas an-
tibodies or with grB and Ad for the times indicated in the
presence or absence of zVAD-fmk. After treatment, cells
were rendered permeable with digitonin and the mito-
chondrial fraction was separated from the cytosol as de-
scribed previously (39). The proteins from these fractions
were examined for Bid by immunoblotting (Fig. 2 A). We
first confirmed the translocation of tBid in response to anti-
Fas treatment (Fig. 2 A, lanes 1–12). In the absence of
zVAD-fmk, cytosolic Bid was cleaved into 15-kD tBid,
which was detectable in the mitochondrial fraction within
2–4 h after anti-Fas addition (Fig. 2 A, lanes 5 and 6). After
longer incubation times, a greater quantity of tBid was seen
in the mitochondrial fraction (Fig. 2 A, compare lanes 5
Figure 1. GrB-mediated cyto-
chrome c release from isolated mi-
tochondria requires Bid. Purified
Jurkat mitochondria were treated
with grB and/or Jurkat cytosol for 30 min at room tempera-
ture in the presence or absence of 100 mM zVAD-fmk. The
mitochondria/cytosol mixture was then centrifuged and the
pellets (mitochondria) and supernatants (cytosol) were re-
solved on 15% polyacrylamide gels followed by transfer to
nitrocellulose and immunoblotting for cytochrome c. M,
mitochondria; C, cytosol; C (mock), mock immunodepleted
cytosol; C (2Bid), cytosol immunodepleted for Bid. These
data are representative of three independent experiments.
Figure 2. Cytosolic Bid is cleaved and
translocates to mitochondria in response to
grB and Ad. (A) Jurkat targets were treated
with either anti-Fas antibodies (lanes 1–12)
or grB and Ad (lanes 13–20) in the presence
or absence of 100 mM zVAD-fmk. After in-
cubation at 378C for the times indicated,
the plasma membranes of cells were ren-
dered permeable with digitonin. The mem-
brane fraction (containing mitochondria)
was then separated from the cytosol by cen-
trifugation. The pellets (mitochondrial frac-
tion) were resolved on 15% polyacrylamide
gels followed by transfer to nitrocellulose
and immunoblotting for Bid using a rabbit
polyclonal anti-Bid antiserum. (B) The su-
pernatant blots from A were stripped and
reprobed for cytochrome c using a mono-
clonal anti–cytochrome c antibody. These
data are representative of three independent
experiments. 
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and 6). In the presence of zVAD-fmk, the generation of
tBid in response to Fas receptor ligation and its accumula-
tion in mitochondria was not observed. These data are
consistent with those published previously (17, 18).
In response to treatment with grB and Ad, 14-kD gtBid
was generated that was detectable in the mitochondrial frac-
tion within 1 h after treatment (Fig. 2 A, lanes 15 and 16).
In addition to 14-kD gtBid, 15-kD tBid was also generated
which translocated to mitochondria (Fig. 2 A, lane 16).
However, in the presence of zVAD-fmk only 14-kD gtBid
was seen in the mitochondria (Fig. 2 A, lane 20), indicating
that the 15-kD band was likely caspase-8–generated tBid.
The blots shown in Fig. 2 A were stripped and reprobed
for cytochrome c as a control for mitochondrial dysfunc-
tion (Fig. 2 B). After anti-Fas treatment, cytochrome c re-
lease was observed (Fig. 2 B, lanes 1–6), detectable cyto-
chrome c release corresponding to the appearance of
detectable tBid at the mitochondria (compare lanes 4–6,
Fig. 2 A with lanes 4–6, Fig. 2 B). In the presence of
zVAD-fmk, no cytochrome c release was observed after
anti-Fas treatment (Fig. 2 B, compare lanes 1–6 and 7–12),
consistent with the caspase dependence of Fas-mediated
cytochrome c release in Jurkats. Similarly, grB-dependent
loss of cytochrome c from mitochondria was observed (Fig.
2 B, lane 16) at the same time as gtBid was detected associ-
ated with mitochondria (compare lanes 13–20, Fig. 2 A,
with lanes 13–20, Fig. 2 B). However, unlike anti-Fas
treatment, cytochrome c efflux occurred with similar ki-
netics in the presence of zVAD-fmk after treatment with
grB and Ad (Fig. 2 B, compare lanes 15 and 16 with 19 and
20). Thus, in whole cells, Bid cleavage by grB generated
14-kD gtBid, which translocated to mitochondria coinci-
dent with the efflux of cytochrome c.
 
Bax Is Integrated into the Mitochondrial Membrane after GrB
and Adenovirus Treatment.
 
Like Bid, another proapoptotic
Bcl-2 family member, Bax, has been implicated in cyto-
chrome c release (44–47). In some cases, Bid activation
leads to a translocation or conformational change in Bax
and its subsequent insertion into the outer mitochondrial
membrane (48–52). To investigate whether Bax might be
involved in grB-mediated cytochrome c release, we used
our whole cell killing system as indicated. Mitochondria
were isolated from Jurkat targets after treatment with grB
and Ad and then subjected to alkaline extraction in 0.1 M
Na
 
2
 
CO
 
3
 
, which strips away proteins peripherally associated
with membranes while leaving integral membrane proteins
intact (52). Bax was found in the cytosolic fraction and pe-
ripherally associated with mitochondria (data not shown)
but not integrated into the mitochondrial membrane in
control cells (Fig. 3, compare lanes 1 and 6) or cells treated
with either grB alone (Fig. 3, lanes 2 and 7) or Ad alone
(Fig. 3, lanes 3 and 8). However, after incubation with
both grB and Ad together, the levels of cytosolic Bax de-
creased (Fig. 3, compare lanes 1 and 4) and Bax was found
integrated into mitochondria (Fig. 3, lane 9). Loss of Bax
from the cytosol and its appearance in the mitochondrial
membrane were also observed in the presence of zVAD-
fmk (Fig. 3, lane 10). These data suggest that in response to
treatment with grB and Ad, Bax becomes integrated into
the mitochondrial membranes of targets through a caspase-
independent process.
 
GrB-mediated Integration of Bax into the Mitochondrial Mem-
brane Is Dependent on Bid.
 
As both gtBid translocation to
mitochondria and Bax integration into mitochondrial
membranes occurred in response to grB and Ad in whole
cells (Figs. 2 A and 3), we sought to elucidate the relation-
ship between Bax and Bid in grB-mediated cytochrome c
release. To this end, we treated isolated Jurkat mitochon-
dria under various conditions followed by alkaline extrac-
tion (Fig. 4). Bax was not found integrated with either
mitochondria alone or mitochondria treated with Jurkat cy-
tosol (Fig. 4, lanes 1 and 2). However, when mitochondria
were exposed to cytosol in conjunction with grB, Bax was
integrated into the membrane as indicated by the increase
in the intensity of Bax immunolabeling in alkali-treated
mitochondria (Fig. 4, lane 3). When mock-immunode-
pleted cytosol was used in place of regular Jurkat cytosol, no
difference in Bax insertion was observed (Fig. 4, lane 4). In
contrast, when Bid was immunodepleted from Jurkat cyto-
sol and the cytosol subsequently added to mitochondria in
combination with grB, Bax insertion was abrogated (Fig. 4,
lane 5). Indeed, in the absence of any other cytosolic com-
ponents, rBid in combination with grB was able to induce
Bax integration into the mitochondrial membrane (Fig. 4,
lane 7). Detectable levels of Bax are found peripherally as-
sociated with Jurkat mitochondria (data not shown), which
provided a source of Bax in the absence of cytosol. Presum-
ably, the requirement for Bax insertion was gtBid, as Bax
insertion did not occur with rBid in the absence of grB
(Fig. 4, lane 6). We observed the same results in the pres-
ence of zVAD-fmk (Fig. 4, lanes 8–12), which indicated
that in the granzyme system, caspases are not required for
Figure 3. Bax is integrated into the mitochondrial membrane in re-
sponse to grB and Ad. Jurkat targets were treated either with nothing
(control [ctrl]), grB alone, Ad alone, or grB and Ad (grB/Ad) in the pres-
ence or absence of 100 mM zVAD-fmk for 3 h at 378C. After incubation,
the plasma membranes of cells were rendered permeable with digitonin.
The permeable cells were then centrifuged to separate the pellets (con-
taining mitochondria) from the supernatants (cytosol). Pellets were sub-
jected to an alkaline extraction with 0.1 M Na2CO3 for 30 min on ice
followed by centrifugation. The pellets and the prealkaline extraction su-
pernatants were resolved on 15% polyacrylamide gels. Proteins were
transferred to nitrocellulose and the blots were probed with polyclonal
anti-Bax antibodies. These data are representative of three independent
experiments. 
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Bax insertion. GrB-mediated Bax integration into rat heart
mitochondria was also dependent on Bid when HeLa cyto-
solic extracts were used (data not shown)
 
Bcl-2 Does Not Block GrB-mediated Bid Cleavage and
Translocation but Does Prevent Bax Insertion and Cytochrome c
Release.
 
Both Bid and Bax have been implicated in cyto-
chrome c release (17–19, 44–47). In our system, Bax inser-
tion into mitochondria did not occur unless Bid was also
present and processed by grB (Fig. 4). We wanted to deter-
mine if both Bid and Bax were required for grB-mediated
cytochrome c release and if so, to determine the order of
recruitment of these proteins. The easiest method to inves-
tigate this would have been to immunodeplete Bax from
cytosolic extracts and examine this effect on mitochondria
in the presence of grB. However, Jurkat mitochondria have
significant levels of peripherally associated Bax after isola-
tion (data not shown), precluding such an experimental ap-
proach. Nevertheless, Bcl-2 overexpression has been
shown to block Bax translocation to mitochondria and sub-
sequent cytochrome c release (53–56). We therefore exam-
ined the effect of grB on Bid and Bax in Jurkat cells over-
expressing Bcl-2 and in vector-only transfectants (Fig. 5).
Cells were manipulated as described for Fig. 2. As with
parental Jurkat cells (Fig. 2 B), cytochrome c release oc-
curred in the vector-only transfectants (neo), detectable
within 1 h after treatment with grB and Ad (Fig. 5 A, lanes
1–4). However, cytochrome c was not detected in super-
natants of Bcl-2 overexpressers under identical conditions
(Fig. 5 A, lanes 5–8). Therefore, as has been previously
published for a variety of apoptotic stimuli (40, 57, 58),
Bcl-2 blocked cytochrome c release in our system.
We next examined Bid cleavage and translocation. Simi-
lar to parental Jurkat cells (Fig. 2), Bid was processed to gt-
Bid in the neo clones and detectable gtBid was found asso-
ciated with mitochondria within 1 h after grB and Ad
treatment (Fig. 5 B, lanes 1–4). Importantly, gtBid was also
found to be associated with mitochondria in the Bcl-2
overexpressers with identical kinetics to the vector-only
controls (Fig. 5 B, lanes 5–8).
Finally, we investigated the effect of Bcl-2 overexpres-
sion on Bax integration into the mitochondrial membrane
(Fig. 5 C). For these experiments, cells were manipulated as
described for Fig. 3. The ideal control for these experi-
ments would have been to compare the vector-only (neo)
Figure 4. GrB-mediated Bax integration into mitochondria requires
Bid. Purified Jurkat mitochondria (M) were treated with grB and cytosol
(C) for 30 min at room temperature in the presence or absence of 100
mM zVAD-fmk. Mitochondria were also treated with grB in the presence
of mock-immunodepleted cytosol (C [mock]) and cytosol immunode-
pleted for Bid (C [2Bid]) as well as rBid. After a 30-min incubation at
room temperature, the mitochondria were subjected to an alkaline ex-
traction with 0.1 M Na2CO3 for 30 min on ice followed by centrifuga-
tion. The pellets were resuspended in buffer A and resolved on 15%
polyacrylamide gels, followed by transfer to nitrocellulose and immuno-
blotting for Bax. These data are representative of three independent ex-
periments.
Figure 5. Bcl-2 blocks grB-
mediated Bax insertion and cy-
tochrome c release but not Bid
processing and translocation. (A)
Vector-only transfected controls
(neo) and Bcl-2–overexpressing
Jurkats were treated with grB
and Ad for the times indicated.
After incubation, cells were frac-
tionated and the proteins were
resolved by SDS-PAGE on 15%
gels and transferred to nitrocellu-
lose. Cytosols were probed with
a monoclonal anti–cytochrome c
antibody. (B) The mitochondrial
fraction from A was probed for
Bid using a polyclonal anti-Bid
antiserum. (C) Jurkat and Bcl-2–
overexpressing Jurkat cells were
treated with grB and Ad as indi-
cated followed by subfraction-
ation as described in Materials
and Methods. The mitochondria
were subjected to alkaline ex-
traction followed by SDS-PAGE
on 15% gels and transferred to
nitrocellulose. Blots were probed with polyclonal anti-Bax antibodies. (D) Mitochondrial fractions from C were overexposed, scanned, and then ana-
lyzed with Image Gauge software to determine relative band intensities. 
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transfectants with the Bcl-2 overexpressers as for Bid and
cytochrome c above (Fig. 5, A and B). However, our neo
clones displayed unusually low levels of Bax relative to the
parental Jurkat line (data not shown). Therefore, we com-
pared the effects on Bax integration in the Bcl-2 overex-
pressers to the parental Jurkat line. Bax integration in Jurkat
cells was detectable within 2 h after grB and Ad treatment
(Fig. 5 C, lanes 1–3). However, no Bax incorporation was
observed in the Bcl-2–overexpressing cells (Fig. 5 C, lanes
4–6). A slight difference in the quantity of cytosolic Bax
between parental Jurkat and Bcl-2 overexpressers was seen
when the blots were scanned and the intensity of the bands
measured. At time zero, the intensity of the Bax band of
the Bcl-2 overexpressers was 
 
z13% lower than that of the
parental Jurkat line (data not shown). The fact that there
was slightly less cytosolic Bax in the Bcl-2 transfectants
might suggest that the absence of Bax in the mitochondrial
fraction simply resulted from less starting material. How-
ever, when the blots containing the mitochondrial fractions
were overexposed overnight (Fig. 4 D) and the intensity of
the bands corresponding to Bax was measured (Fig. 4 D), a
nearly 15-fold increase in intensity of Bax was seen in the
parental Jurkat mitochondria after 2 h. In contrast, no more
than a threefold increase was seen with the Bcl-2 transfec-
tants. If Bax integration into mitochondria occurred despite
the presence of Bcl-2, an z13% decrease in the starting
levels of Bax would still allow it to be detected in mito-
chondria, particularly with longer exposures. However,
virtually no Bax was detected at longer exposures. Collec-
tively, these data indicated that the overexpression of Bcl-2
blocked grB-mediated Bax integration into mitochondria
and cytochrome c release, but did not affect Bid processing
and translocation.
Discussion
The induction of apoptosis in a pathogenic cell under at-
tack by a CTL is known to involve grB activation of
caspases, notably caspase-3. However, this paradigm does
not explain the caspase-independent arm of CTL-mediated
death. Our previous experiments demonstrated that mito-
chondrial changes might be an important component of
the death machinery activated by CTLs (39). As cyto-
chrome c efflux in response to grB occurred in a caspase-
independent fashion, grB was either acting directly on mi-
tochondria to induce cytochrome c release, or indirectly
through a cellular substrate that was not a caspase. Data
presented here indicate that grB alone is unable to elicit the
release of cytochrome c from purified mitochondria (Figs.
1 and 2). Rather, the proapoptotic Bcl-2 family members
Bid and Bax are required in conjunction with grB.
We examined whether Bid was required for cytochrome
c efflux in an in vitro system using purified Jurkat mito-
chondria and purified Jurkat cytosol. Immunodepletion of
Bid from the cytosol abolished, whereas reintroduction of
recombinant Bid (rBid) to the Bid-depleted cytosol re-
stored the ability of grB to induce cytochrome c efflux.
These data are consistent with those already published, in-
dicating that the immunodepletion of Bid from TNF/
cycloheximide-treated cytosolic extracts prevented cyto-
chrome c release (19). However, in our system, grB had to
be present in conjunction with cytosol, suggesting that Bid
is processed either directly or through other granzyme-acti-
vated proteinases.
In the absence of cytosol, the addition of rBid to mito-
chondria was an insufficient stimulus for cytochrome c re-
lease. However, cytochrome c efflux was accomplished by
adding grB and rBid to mitochondria, indicating that
caspases were clearly not required to mediate this effect.
These data contrast with the process of Bid cleavage char-
acterized for the Fas pathway that depends on caspase-8 to
process Bid (17, 18).
In response to ligation of the Fas receptor, caspase-8
cleavage of Bid at Asp59 generates a 15-kD tBid COOH-
terminal fragment. Removal of the NH2 terminus of Bid
exposes the otherwise inaccessible BH3 domain found in
the COOH terminus of full-length Bid (59, 60). Once
formed, tBid rapidly translocates to mitochondria to induce
cytochrome c release through an ill-defined mechanism
(17–19). Processing of Bid by grB at Asp75 generates a 14-
kD gtBid product (18) that, like tBid, contains the BH3
domain. Despite the different site of cleavage and the
smaller size of the cleavage product, gtBid was found local-
ized to mitochondria in whole cells in response to treat-
ment with grB and Ad. As the BH1, BH2, and BH3 do-
mains of Bcl-2/Bcl-XL can act as a binding pocket for the
BH3 domains of other Bcl-2 family members (20, 61),
freeing the BH3 domain of Bid may allow it to het-
erodimerize with Bcl-2/Bcl-XL on the mitochondrial
membrane. In support of this notion, one study reported
that recombinant tBid had a 10-fold higher affinity for glu-
tathione S-transferase (GST)-Bcl-XL than did full-length
Bid (18). In addition, mutations in Bid’s BH3 domain that
prevented its binding to Bcl-2/Bcl-XL also blocked cyto-
chrome c release and apoptosis (17, 19, 20). However,
these BH3 mutations did not block translocation of Bid to
mitochondria. In addition to exposing the BH3 domain,
the removal of the NH2 terminus of Bid increases the sur-
face hydrophobicity of tBid and alters its surface charge (59,
60). It is these changes, rather than exposure of the BH3
domain, which may allow tBid to target membranes. Nev-
ertheless, by whatever mechanism tBid associates with mi-
tochondria, the regions of tBid that are required for this
process are clearly also present in gtBid.
In the absence of zVAD-fmk, tBid was also generated in
response to grB and Ad treatment (35). Although not re-
quired for apoptosis, grB can cleave and activate caspase-8
(35). As tBid is generated by caspase-8, it remained possible
that despite the presence of gtBid, cytochrome c release re-
sulted from tBid translocation alone. However, we showed
here that in the presence of zVAD-fmk, cytochrome c re-
lease occurred but only gtBid was detected. Importantly,
detectable cytochrome c release paralleled detectable gtBid
translocation either in the absence or presence of zVAD-
fmk. This indicated that the smaller gtBid was equivalent to
the larger caspase-8–generated tBid in its ability to induce1398 Granzyme B–mediated Cytochrome c Release Is Regulated by Bid and Bax
cytochrome c efflux from mitochondria. Therefore, our in
vitro and in vivo data demonstrate for the first time that
caspase-independent cytochrome c release is dependent on
grB-mediated cleavage of Bid and the subsequent translo-
cation to mitochondria of gtBid.
The mechanism by which Bid induces cytochrome c
release remains elusive. Nevertheless, mounting evidence
suggests that, at least in some cases, the relocalization of
tBid functions to recruit another proapoptotic Bcl-2 family
member, Bax, to mitochondria (56). Bax recruitment may
occur through a tBid-induced conformational change in
Bax that allows it to insert into the mitochondrial outer
membrane (55). In Jurkat cells after treatment with grB and
Ad, Bax was found to integrate into mitochondrial mem-
branes in both the presence and absence of zVAD-fmk.
These results are consistent with data showing that in the
presence of recombinant tBid, Bax translocation to mito-
chondria and its integration into the outer membrane do
not rely on caspases (53, 55, 56). Here we show that Bax
integration in response to grB also occurred with purified
mitochondria in a caspase-independent fashion, but only
when Bid was present in cytosolic extracts. Thus, as de-
scribed previously for tBid, gtBid was able to recruit Bax to
mitochondria.
What role Bax may play in gtBid-induced cytochrome c
release is unclear. Bax itself has been shown to induce cyto-
chrome c release in isolated mitochondria (44–47) and
when overexpressed in whole cells (62). Recently, Bax was
shown to interact with the voltage-dependent anion chan-
nel (VDAC) in the outer mitochondrial membrane to form
a cytochrome c conducting channel (45, 63, 64). Bax
may also interact with the adenine nucleotide transporter
(ANT) on the inner mitochondrial membrane to cause a
permeability transition leading to an indirect release of cy-
tochrome c (65). Cyclosporine, an inhibitor of the perme-
ability transition, blocked this Bax-mediated cytochrome c
release (65). However, other evidence indicates that Bax-
mediated cytochrome c release is cyclosporine insensitive
and therefore independent of the permeability transition
(55). This argues that the manner in which Bax affects cy-
tochrome c release may be differentially regulated in differ-
ent cells and/or in response to different apoptotic stimuli.
In the granzyme system, both inner mitochondrial mem-
brane potential loss and cell death seen in whole cells are
cyclosporine independent (39, 40), arguing that the recruit-
ment of Bax to mitochondria and its role in cytochrome c
release are independent of the permeability transition.
Bcl-2 has been reported to block cytochrome c release in
response to a variety of apoptotic stimuli (57, 58). Further,
Bcl-2 blocks both translocation of Bax from the cytosol to
mitochondria and its subsequent insertion into the outer
membrane (53–56). In response to grB and Ad treatment,
no cytochrome c release was seen in Jurkat cells overex-
pressing Bcl-2. However, even with Bcl-2 overexpression,
grB-dependent Bid cleavage still occurred and gtBid was
found relocalized to mitochondria. Despite gtBid transloca-
tion to mitochondria in the presence of Bcl-2, no Bax inte-
gration into the mitochondrial membrane was observed.
The Bcl-2–antagonized integration of Bax correlated with
the absence of cytochrome c release in response to grB and
Ad. Thus, whereas gtBid was localized to mitochondria in
the Bcl-2–overexpressing cells, no cytochrome c release
was observed in the absence of Bax integration. We cannot
rule out the possibility that the levels or functions of other
Bcl-2 family members may be altered in the Bcl-2 transfec-
tants and that the effects of these proteins may influence the
movement of Bax to mitochondria. Nevertheless, there is
now growing evidence in the literature to link Bid with
Bax recruitment to mitochondria (55, 56, 66). In addition,
the literature supports a model whereby Bax recruitment
can be antagonized by Bcl-2 (53, 54, 67). Finally, evidence
suggests that Bax is able to induce the efflux of cytochrome
c from mitochondria (44, 45, 47, 48, 56, 68). We have not
shown that cytochrome c release absolutely depends on
Bax integration into the mitochondrial outer membrane in
the granzyme system. However, the fact that cytochrome c
release does not occur in the absence of Bax integration
coupled with the available literature renders this hypothesis
plausible.
Collectively, our data support a model in which grB pro-
teolytically cleaves Bid to generate a 14-kD gtBid fragment
Figure 6. Model for regulation by Bcl-2 family members of grB-
mediated cytochrome c release. GrB may activate caspase-3 directly, or
indirectly through the proteolytic activation of Bid. Bid is cleaved to
generate gtBid that translocates to mitochondria where it recruits Bax
through a mechanism antagonized by Bcl-2. Bax becomes integrated
into the mitochondrial membrane and induces cytochrome c release.
Cytochrome c acts as a cofactor with Apaf-1, caspase-9, and ATP/dATP
to foster the proteolytic activation of caspase-3. DCm, inner mitochon-
drial membrane potential.1399 Heibein et al.
that translocates to mitochondria through a caspase-inde-
pendent mechanism (Fig. 6). gtBid localized to mitochon-
dria then recruits Bax to the mitochondrial outer mem-
brane through a mechanism antagonized by Bcl-2. Once
integrated, Bax initiates cytochrome c release from mito-
chondria through a cyclosporine-independent mechanism.
It has been suggested that caspase inhibitors may be ef-
fective in the treatment of autoimmune disorders and sup-
pression of transplant rejection. Our results imply that these
alone would be ineffective. Rather, therapeutic interven-
tions that block both caspase and mitochondrial pathways
would be required. The relative importance of these mech-
anisms in cell death in vivo is currently under investigation.
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